Effects of androgen modifying therapies on disease activity in older men with multiple sclerosis

IF 2.5 4区 医学 Q3 IMMUNOLOGY Journal of neuroimmunology Pub Date : 2025-06-15 Epub Date: 2025-03-18 DOI:10.1016/j.jneuroim.2025.578589
Burcu Zeydan , Nur Neyal , Nabeela Nathoo , Manu Rangachari , Elizabeth J. Atkinson , Jiye Son , Brittani L. Conway , W. Oliver Tobin , B. Mark Keegan , Brian G. Weinshenker , Kejal Kantarci , Jiwon Oh , Orhun H. Kantarci
{"title":"Effects of androgen modifying therapies on disease activity in older men with multiple sclerosis","authors":"Burcu Zeydan ,&nbsp;Nur Neyal ,&nbsp;Nabeela Nathoo ,&nbsp;Manu Rangachari ,&nbsp;Elizabeth J. Atkinson ,&nbsp;Jiye Son ,&nbsp;Brittani L. Conway ,&nbsp;W. Oliver Tobin ,&nbsp;B. Mark Keegan ,&nbsp;Brian G. Weinshenker ,&nbsp;Kejal Kantarci ,&nbsp;Jiwon Oh ,&nbsp;Orhun H. Kantarci","doi":"10.1016/j.jneuroim.2025.578589","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Anti-inflammatory properties of androgens were assessed in animal models, but only several clinical studies investigated the effects of androgen on multiple sclerosis (MS). Inflammatory activity in MS often attenuates with aging, and androgen modifying therapies (AMT), which mimic decreased androgen levels, are frequently used in older men. We aimed to investigate if the number of disease activity events would increase in older (≥55 years) male persons with MS (MPwMS) who are on AMT.</div></div><div><h3>Methods</h3><div>MPwMS with AMT initiation ≥55 years (AMT; <em>n</em> = 60) and without AMT history (no-AMT; <em>n</em> = 80) were included from a clinical-based observational study cohort. <em>Clinical</em> (relapses), <em>Radiological</em> (new lesions), and <em>Disease</em> (relapses and/or new lesions) <em>activity</em> events were evaluated before and after the age at AMT initiation in AMT and no-AMT groups.</div></div><div><h3>Results</h3><div>Age at MS onset, progressive MS rate and treatment frequencies were similar between the groups. When events before and after the age at AMT initiation (mean = 65.0 ± 7.0 years) were compared, there was a drop in the percentage of individuals with <em>Clinical</em> (38.5 % vs. 10 %), <em>Radiological</em> (46.2 % vs. 40 %) and <em>Disease</em> (62.8 % vs. 40 %) <em>activity</em> events in the no-AMT group. In the AMT group, the percentage of individuals with <em>Clinical activity</em> events was not as dramatically decreased (33.3 % vs. 22.2 %), <em>Radiological activity</em> events was increased (35.2 % vs. 46.7 %), and <em>Disease activity</em> events was sustained (51.9 % vs. 51.1 %). The probability of <em>Disease activity</em> was higher in the AMT group at 3 years of AMT initiation (40 % vs. 29 %) compared to the no-AMT group matched for disease duration, but the difference was not significant (<em>p</em> = 0.582).</div></div><div><h3>Conclusions</h3><div>Rather than the expected decrease in disease activity with age, MPwMS receiving AMT experienced sustained or increased disease activity, particularly at &gt;65 years. Close clinical monitoring of MPwMS starting on these medications is necessary.</div></div>","PeriodicalId":16671,"journal":{"name":"Journal of neuroimmunology","volume":"403 ","pages":"Article 578589"},"PeriodicalIF":2.5000,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neuroimmunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165572825000694","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Anti-inflammatory properties of androgens were assessed in animal models, but only several clinical studies investigated the effects of androgen on multiple sclerosis (MS). Inflammatory activity in MS often attenuates with aging, and androgen modifying therapies (AMT), which mimic decreased androgen levels, are frequently used in older men. We aimed to investigate if the number of disease activity events would increase in older (≥55 years) male persons with MS (MPwMS) who are on AMT.

Methods

MPwMS with AMT initiation ≥55 years (AMT; n = 60) and without AMT history (no-AMT; n = 80) were included from a clinical-based observational study cohort. Clinical (relapses), Radiological (new lesions), and Disease (relapses and/or new lesions) activity events were evaluated before and after the age at AMT initiation in AMT and no-AMT groups.

Results

Age at MS onset, progressive MS rate and treatment frequencies were similar between the groups. When events before and after the age at AMT initiation (mean = 65.0 ± 7.0 years) were compared, there was a drop in the percentage of individuals with Clinical (38.5 % vs. 10 %), Radiological (46.2 % vs. 40 %) and Disease (62.8 % vs. 40 %) activity events in the no-AMT group. In the AMT group, the percentage of individuals with Clinical activity events was not as dramatically decreased (33.3 % vs. 22.2 %), Radiological activity events was increased (35.2 % vs. 46.7 %), and Disease activity events was sustained (51.9 % vs. 51.1 %). The probability of Disease activity was higher in the AMT group at 3 years of AMT initiation (40 % vs. 29 %) compared to the no-AMT group matched for disease duration, but the difference was not significant (p = 0.582).

Conclusions

Rather than the expected decrease in disease activity with age, MPwMS receiving AMT experienced sustained or increased disease activity, particularly at >65 years. Close clinical monitoring of MPwMS starting on these medications is necessary.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
雄激素修饰疗法对老年男性多发性硬化症患者疾病活动性的影响
雄性激素的抗炎特性在动物模型中被评估,但只有几项临床研究调查了雄性激素对多发性硬化症(MS)的影响。多发性硬化症的炎症活动通常随着年龄的增长而减弱,而雄激素修饰疗法(AMT),一种模拟雄激素水平下降的疗法,经常用于老年男性。我们的目的是调查老年(≥55岁)男性多发性硬化症患者(MPwMS)接受AMT治疗时疾病活动事件的数量是否会增加。方法AMT起始≥55年(AMT;n = 60),无AMT病史(no-AMT;N = 80)来自临床观察性研究队列。在AMT组和非AMT组中,评估AMT起始年龄前后的临床(复发)、放射学(新病变)和疾病(复发和/或新病变)活动事件。结果两组间MS发病年龄、进展性MS发生率及治疗频率相似。当比较AMT开始年龄(平均= 65.0±7.0岁)前后的事件时,无AMT组出现临床(38.5%比10%)、放射(46.2%比40%)和疾病(62.8%比40%)活动事件的个体百分比有所下降。在AMT组中,有临床活动事件的个体百分比没有显著下降(33.3%对22.2%),放射活动事件增加(35.2%对46.7%),疾病活动事件持续(51.9%对51.1%)。与疾病持续时间匹配的无AMT组相比,AMT组在AMT开始3年时疾病活动的概率更高(40% vs. 29%),但差异不显著(p = 0.582)。结论:与预期的疾病活动性随年龄增长而下降相反,接受AMT治疗的MPwMS的疾病活动性持续或增加,尤其是在65岁时。从这些药物开始密切监测MPwMS是必要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of neuroimmunology
Journal of neuroimmunology 医学-免疫学
CiteScore
6.10
自引率
3.00%
发文量
154
审稿时长
37 days
期刊介绍: The Journal of Neuroimmunology affords a forum for the publication of works applying immunologic methodology to the furtherance of the neurological sciences. Studies on all branches of the neurosciences, particularly fundamental and applied neurobiology, neurology, neuropathology, neurochemistry, neurovirology, neuroendocrinology, neuromuscular research, neuropharmacology and psychology, which involve either immunologic methodology (e.g. immunocytochemistry) or fundamental immunology (e.g. antibody and lymphocyte assays), are considered for publication.
期刊最新文献
Soluble c-Met correlates with NfL and GFAP levels in the CSF of patients with multiple sclerosis Rethinking rituximab in neuroimmunology: Real-world efficacy, cost-effectiveness, and long-term remission Irf8 exacerbates hypertensive intracerebral hemorrhage by mediating a pro-inflammatory phenotype of microglia through the Stat1/Trim5 axis Astrocyte-specific FoxF2 modulates immune and myelin repair: Evidence from multiple sclerosis lesions and an animal model Morvan syndrome associated with prominent Tau pathology: A clinicopathological case report
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1